Stay updated on Durvalumab and Tremelumab in Hepatocellular Carcinoma Clinical Trial
Sign up to get notified when there's something new on the Durvalumab and Tremelumab in Hepatocellular Carcinoma Clinical Trial page.

Latest updates to the Durvalumab and Tremelumab in Hepatocellular Carcinoma Clinical Trial page
- Check3 days agoChange DetectedThe web page has been updated from version 2.16.2 to version 2.16.3.SummaryDifference0.0%
- Check10 days agoChange DetectedThe web page has been updated from version 2.16.1 to version 2.16.2.SummaryDifference0.0%
- Check18 days agoChange DetectedThe web page has been updated to reflect the upcoming modernization of the ClinicalTrials.gov data ingest scheduled for June 2025, along with an updated version number from v2.16.0 to v2.16.1.SummaryDifference0.7%
- Check25 days agoChange DetectedThe web page has been updated to version 2.16.0, replacing the previous version 2.15.2.SummaryDifference0.1%
- Check47 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2, indicating a revision in the content.SummaryDifference0.0%
- Check62 days agoChange DetectedThe page has been updated to include the term 'Hepatocellular Carcinoma' and a new registry identifier, while significant details about the study's design, participant criteria, and treatment protocols have been removed.SummaryDifference13%
Stay in the know with updates to Durvalumab and Tremelumab in Hepatocellular Carcinoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Durvalumab and Tremelumab in Hepatocellular Carcinoma Clinical Trial page.